SEOM clinical guidelines for the management of germ cell testicular cancer (2016)

• J. Aparicio ^[7] ; J. Terrasa ^[1] ; I. Durán ^[2] ; J. R. Germà-Lluch ^[3] ; R. Gironés ^[4] ; E. González-Billalabeitia ^[8] ; J. Gumà ^[9] ; P. Maroto ^[5] ; A. Pinto ^[6] ; X. García-del-Muro ^[3]
  1. [1] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  2. [2] Instituto de Biomedicina de Sevilla

     Instituto de Biomedicina de Sevilla

     Sevilla, España

     
  3. [3] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  4. [4] Hospital Xàtiva Lluis Alcanyis

     Hospital Xàtiva Lluis Alcanyis

     Játiva, España

     
  5. [5] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  6. [6] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  7. [7] Hospital Universitario y Politécnico La Fe, España
  8. [8] Hospital Universitario Morales Meseguer, España
  9. [9] Hospital Universitario Sant Joan de Reus, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1187-1196
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Testicular cancer represents the most common malignancy in males aged 15–34 years and is considered a model of curable neoplasm. Maintaining success, reducing treatment burden, and focusing on survivorship are then key objectives. Inguinal orchiectomy is the first recommended maneuver that has both diagnostic and therapeutic aims. Most patients are diagnosed with stage I disease (confined to the testicle). Close surveillance and selective, short-course adjuvant chemotherapy are accepted alternatives for these cases. In patients with more advanced disease (stages II and III), 3–4 courses of cisplatin-based chemotherapy (according to IGCCCG risk classification) followed by the judicious surgical removal of residual masses represent the cornerstone of therapy. Poor-risk patients and those failing a first-line therapy should be referred to specialized tertiary centers. Paclitaxel-based conventional chemotherapy and high-dose chemotherapy plus autologous hematopoietic support can cure a proportion of patients with relapsing or refractory disease.